BiomaterialsBioprintingCareer Moves

Biogelx welcomes new CEO Alison Clayton

Clayton will replace recently retired Mitch Scanlan

Scotland-based biomaterials firm Biogelx has announced the appointment of a new CEO, Alison Clayton. Clayton will take over the leading position from Mitch Scanlan, who recently retired. The company has also announced the appointment of Margaret Temple to its board of directors as well as the completion of a successful round of fundraising.

Clayton has over 25 years of experience working in the contract testing industry, working for companies including Eurofins, Quintiles and Aptuit. The new Biogelx CEO also holds a degree and PhD in Pharmacology from the University of Glasgow and spent seven years conducting research in several post-doctoral positions. Clayton will bring this varied experience to Biogelx, a company that specializes in the production of synthetic bioprinting materials.

“We are absolutely delighted to have Alison come on board here at Biogelx,” said John Waddell, the company’s Chairman. “Her commercial experience coupled with her academic background will help move the company to the next phase of its evolution.”

Biogelx Synthetic Bioinks Alison Clayton CEO

“I am excited to be joining Biogelx at this time when the applications for the products in 3D Bioprinting and also 3D Cell Culture are growing.” added Clayton. “We have extensive collaborations ongoing with both academia and commercial organisations which further develop the applications for the products maximising their utility within the research and development space.”

In addition to the appointment of a new CEO, Biogelx has also welcomed Margaret Temple to its board of directors as non-executive director. Temple has worked in the life sciences industry for over two decades and has over 25 years of experience in the life science CRO sector. In 2007, she co-founded biopharmaceutical company Vitrology Ltd. and served as CEO until it was acquired by Swiss multinational SGS in 2012.

To round off its new appointments, Biogelx has also revealed it has closed a successful round of financing, the funding from which will enable it to continue its growth and the development of new hydrogel and bioink products for bioprinting and 3D cell culture. The funding round saw participation from the University of Strathclyde, the Scottish Investment Bank and their private investors.


Tess Boissonneault

Tess Boissonneault moved from her home of Montreal, Canada to the Netherlands in 2014 to pursue a master’s degree in Media Studies at the University of Amsterdam. It was during her time in Amsterdam that she became acquainted with 3D printing technology and began writing for a local additive manufacturing news platform. Now based in France, Tess has over two and a half years experience writing, editing and publishing additive manufacturing content with a particular interest in women working within the industry. She is an avid follower of the ever-evolving AM industry.

Related Articles

Back to top button

We use cookies to give you the best online experience. By agreeing you accept the use of cookies in accordance with our cookie policy.

Privacy Settings saved!
Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies are necessary for the website to function and cannot be switched off in our systems.

In order to use this website we use the following technically required cookies
  • wordpress_test_cookie
  • wordpress_logged_in_
  • wordpress_sec

Decline all Services
Accept all Services



Join industry leaders and receive the latest insights on what really matters in AM!

This information will never be shared with 3rd parties

I’ve read and accept the privacy policy.*